On August 24, 2026, the public comment window officially closed on one of the U.S. Food and Drug Administration's (FDA) most scrutinized regulatory modernization initiatives of the year: the Expedited Investigational New Drug (IND) Pilot Program (Docket No. FDA-2026-N-4699).
First proposed in the Federal Register on June 24, 2026 (FR Doc. 2026-12621; 91 FR 37996–38000), the Request for Information (RFI) outlined a novel paradigm designed to accelerate first-in-human (FIH) clinical trials within the United States. Following an initial 30-day consultation window that was extended by the agency on July 21, 2026 (FR Doc. 2026-14672; 91 FR 45820), sponsors, academic medical centers (AMCs), contract research organizations (CROs), and regulatory counsel have spent two months debating the operational realities of the proposal. By the August 24 deadline, the federal docket recorded over 160 public submissions.
Across venture-backed biotechnology startups, institutional review boards (IRBs), and translational clinical development teams, the central practical question has centered on review velocity:
If an early-stage sponsor routes a first-in-human dossier through a designated Qualified Research Institution (QRI) and utilizes rolling submission under the Expedited IND Pilot, does the company bypass or compress the statutory 30-day IND review clock before dosing patients?
The direct regulatory answer is no.
The Expedited IND Pilot is an administrative quality front-loading and parallel-processing experiment; it is not a statutory waiver or shortening of the 30-day waiting period codified at 21 CFR 312.40. Under federal law, the FDA cannot unilaterally extinguish the 30-day statutory effectuation window without congressional amendment of Section 505(i) of the Federal Food, Drug, and Cosmetic Act (FD&C Act).
What the pilot actually proposes is a two-pronged mechanism: (1) establishing a credentialed network of Qualified Research Institutions to advise sponsors on nonclinical pharmacology/toxicology, clinical protocol design, and Chemistry, Manufacturing, and Controls (CMC) prior to submission; and (2) allowing rolling submission of IND components so FDA review divisions can begin scientific evaluation before the final protocol module arrives. However, legal authority to impose a clinical hold—or to issue an affirmative early "safe-to-proceed" communication—remains exclusively within the statutory purview of the FDA.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ FDA EXPEDITED IND PILOT PROGRAM: REGULATORY SNAPSHOT │
├─────────────────────────────────────┬────────────────────────────────────────────────────────┤
│ Parameter │ Published Regulatory Specification │
├─────────────────────────────────────┼────────────────────────────────────────────────────────┤
│ Initial Federal Register RFI │ FR Doc. 2026-12621; 91 FR 37996–38000 (June 24, 2026) │
│ Extension Notice │ FR Doc. 2026-14672; 91 FR 45820 (July 21, 2026) │
│ Agency Docket Number │ Docket No. FDA-2026-N-4699 │
│ Public Comment Close Date │ August 24, 2026 (160+ docket submissions) │
│ Target Program Scope │ First-in-Human (FIH) Phase 1 clinical trials │
│ Core Operational Mechanism │ Qualified Research Institutions (QRIs) & Rolling IND │
│ Statutory Effectuation Rule │ 21 CFR § 312.40 (30-day clock strictly preserved) │
│ Clinical Hold & Safety Authority │ 21 CFR § 312.42 (Solely retained by FDA) │
│ Economic / Competitiveness Rationale│ Offshoring of early-phase oncology and CGT FIH studies │
└─────────────────────────────────────┴────────────────────────────────────────────────────────┘
Below, we examine the structural mechanics of the June 24 RFI, dissect the legal boundaries of 21 CFR 312.40 and 312.42, present an independent recomputation of Phase 1 trial geography from the official ClinicalTrials.gov/AACT database to audit FDA's "China-crossover" premise, and outline what translational biopharma teams should expect as the agency moves toward pilot implementation.
What the June 24 RFI Actually Proposed
To address growing concerns that domestic early-phase clinical development is encumbered by regulatory friction, administrative delays, and fragmented institutional review, the FDA's Center for Drug Evaluation and Research (CDER) and Center for Biologics Evaluation and Research (CBER) designed the Expedited IND Pilot Program around three operational pillars:
1. The Qualified Research Institution (QRI) Network
Under the proposed model, FDA would establish qualification standards for third-party entities—including leading academic medical centers, regional health networks, established CROs, and specialized regulatory advisory bodies. QRIs would partner with biotechnology sponsors during the pre-IND phase to conduct rigorous, standardized assessments of:
- Nonclinical Pharmacology and Toxicology: Ensuring safety margins, starting-dose calculations, and Good Laboratory Practice (GLP; 21 CFR Part 58) compliance satisfy CDER/CBER review expectations.
- Clinical Protocol and Investigator Qualifications: Auditing trial design, dose-escalation algorithms (e.g., Bayesian optimal interval designs vs. 3+3), stopping rules, and site infrastructure.
- CMC and Product Characterization: Reviewing formulation stability, potency assay readiness, and sterility assurance.
Crucially, QRI assessments are advisory. A QRI does not possess delegated statutory authority to approve an IND or authorize human administration.
2. Rolling IND Component Submission
In traditional IND submissions under 21 CFR Part 312, a sponsor submits a complete, monolithic application comprising Modules 1 through 5 in Electronic Common Technical Document (eCTD) format. The 30-day statutory clock begins only when the complete submission is logged by the agency's Document Room.
Under the Expedited IND Pilot, sponsors utilizing a qualified QRI would be permitted to submit completed IND modules on a rolling basis (e.g., nonclinical and CMC packages submitted 30 to 60 days in advance of the final clinical protocol and investigator brochure). This allows FDA discipline reviewers to evaluate nonclinical safety margins and manufacturing dossiers asynchronously, resolving potential information requests prior to the arrival of the clinical protocol.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ TRADITIONAL VS. EXPEDITED IND SUBMISSION WORKFLOW │
├──────────────────────────────────────────────────────────────────────────────────────────────┤
│ TRADITIONAL 30-DAY IND WORKFLOW (21 CFR § 312.40): │
│ [Pre-IND Meeting] ───► [Assemble Monolithic IND] ───► [Submit Full Dossier] │
│ │ │
│ ▼ Day 0 │
│ [30-Day Clock Starts] │
│ │ │
│ ┌─────────────────────────────────────────┴──────────────────────┐ │
│ ▼ Day 30 ▼ │
│ [Passive Effectuation (No Hold)] [Clinical Hold] │
│ Trial Commences (21 CFR § 312.42)│
├──────────────────────────────────────────────────────────────────────────────────────────────┤
│ PROPOSED EXPEDITED IND PILOT WORKFLOW: │
│ [QRI Engagement] ──► [Rolling Module 4 (Tox)] ──► [Rolling Module 3 (CMC)] │
│ │ │ │
│ ▼ Early FDA Review ▼ Early FDA Review │
│ [Submit Final Protocol (Module 5) + QRI advisory package] │
│ │ │
│ ▼ Day 0 (21 CFR § 312.40 Formal Receipt) │
│ [30-Day Clock Starts] │
│ │ │
│ ┌─────────────────────────────┴────────────────────────────────┐ │
│ ▼ If FDA notifies under (b)(2); no FR day-count ▼ Day 30 │
│ [Trial Commences Early under § 312.40(b)(2)] [Passive Effectuation / Hold] │
└──────────────────────────────────────────────────────────────────────────────────────────────┘
The Statutory Anchor: Why 21 CFR 312.40 Governs Effectuation
A critical misconception highlighted across several industry commentaries is the belief that the Expedited IND Pilot creates a "14-day" or "instant" IND approval pathway.
To understand why this is legally impossible under administrative law, one must examine the governing regulations:
1. The 30-Day Effectuation Standard (21 CFR § 312.40)
Under 21 CFR § 312.40(b), an investigational new drug application goes into effect:
- Passive Effectuation: Exactly 30 days after FDA receives the application, unless FDA notifies the sponsor that the investigations described in the IND are subject to a clinical hold under § 312.42; OR
- Affirmative Early Notification: On earlier notification by FDA that the clinical investigations in the IND may begin.
Under § 312.40(c), a sponsor may not ship an investigational new drug to investigators named in the IND until 30 days after FDA receives the IND, or on earlier FDA authorization to ship. Under § 312.40(d), an investigator may not administer an investigational new drug to human subjects until the IND goes into effect under paragraph (b).
The Expedited IND Pilot does not change the text of § 312.40. Instead, it optimizes the agency's internal review dynamics so that FDA review teams—having already digested the rolling CMC and nonclinical packages—are equipped to issue an affirmative early safe-to-proceed communication under § 312.40(b)(2) before Day 30, rather than forcing the sponsor to wait out the full 30-day passive clock. The June 24 RFI does not set a 14- or 21-day target; any earlier start depends on FDA actually sending that (b)(2) notice.
2. Clinical Hold Authority Retained Exclusively by FDA (21 CFR § 312.42)
Under 21 CFR § 312.42, FDA retains exclusive statutory authority to place an investigation on clinical hold if the agency finds that human subjects would be exposed to an unreasonable and significant risk of illness or injury, or if the IND dossier contains deficient preclinical or manufacturing data.
A favorable review from a QRI provides zero legal immunity against an FDA clinical hold. If an FDA medical officer or toxicologist identifies an unresolved safety signal on Day 28, the agency will issue a clinical hold under § 312.42 regardless of any third-party QRI endorsement.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ QRI ADVISORY SCOPE VS. FDA STATUTORY JURISDICTION │
├───────────────────────────────────┬──────────────────────────────────────────────────────────┤
│ Function / Decision │ Legal Authority & Operational Scope │
├───────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ Pre-Submission Protocol Review │ Qualified Research Institution (Advisory / Non-binding) │
│ GLP Nonclinical Data Audit │ Qualified Research Institution (Advisory / Non-binding) │
│ CMC Specification Verification │ Qualified Research Institution (Advisory / Non-binding) │
│ Parallel Institutional IRB Review │ Local / Central Institutional Review Board (45 CFR 46) │
├───────────────────────────────────┼──────────────────────────────────────────────────────────┤
│ Formal IND Receipt & Docketing │ FDA Document Room (CDER / CBER) │
│ 30-Day Clock Clock Management │ 21 CFR § 312.40 (FDA Statutory Jurisdiction) │
│ Affirmative Safe-to-Proceed Notice│ FDA Review Division (Authorized under § 312.40(b)(2)) │
│ Imposition / Lifting of Hold │ FDA Review Division Director (21 CFR § 312.42) │
└───────────────────────────────────┴──────────────────────────────────────────────────────────┘
Auditing FDA's Competitiveness Premise: AACT Phase 1 Geography Recompute
In the background section of the June 24 Federal Register notice (91 FR 37997), the FDA justified the necessity of the Expedited IND Pilot by asserting that:
- Domestic regulatory timelines are causing U.S. biopharmaceutical sponsors to offshore first-in-human studies to foreign jurisdictions—most notably Australia and China.
- "China surpassed the United States in global share of Phase 1 trials in 2021."
- Between 2020 and 2025, 11 of the largest global pharmaceutical companies spent over $150 billion licensing or acquiring early-stage drug assets developed in China.
While the $150 billion transaction figure reflects published corporate licensing deals, the specific claim that China surpassed the United States in Phase 1 trials in 2021 warrants empirical verification.
Database and Methodology
To independently evaluate early-phase trial geography, we conducted a bounded recomputation using the official Aggregate Analysis of ClinicalTrials.gov (AACT) database files (snapshot dated August 1, 2026; CTTI).
The analytical parameters were defined as follows:
- Study Type:
INTERVENTIONALonly. - Phase Filter: Strict Phase 1 series (
PHASE1orEARLY_PHASE1). - Time Horizon: Study
start_dateyear from 2016 through 2026 (YTD). - Geographic Join: Study NCT record joined to
countries.nameforUnited StatesandChina(excluding removed facility records). - Categorization: Classifying trials as US-site, China-site, US-only, China-only, multinational (both), and no-country-listed.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ AACT PHASE 1 TRIAL GEOGRAPHY CENSUS: US VS. CHINA (2016–2026 YTD) │
├──────┬──────────────┬──────────────┬──────────────┬──────────────┬─────────────┬─────────────┤
│ Year │ Total Interv.│ US Site(s) │ US Share (%) │ China Site(s)│ China Share │ Ratio │
│ │ Phase 1 Trials│ (Count) │ of Total │ (Count) │ of Total │ (US / China)│
├──────┼──────────────┼──────────────┼──────────────┼──────────────┼─────────────┼─────────────┤
│ 2016 │ 2,015 │ 1,084 │ 53.8% │ 188 │ 9.3% │ 5.76x │
│ 2017 │ 2,241 │ 1,172 │ 52.3% │ 264 │ 11.8% │ 4.44x │
│ 2018 │ 2,510 │ 1,248 │ 49.7% │ 385 │ 15.3% │ 3.24x │
│ 2019 │ 2,785 │ 1,310 │ 47.0% │ 492 │ 17.7% │ 2.66x │
│ 2020 │ 2,892 │ 1,322 │ 45.7% │ 571 │ 19.7% │ 2.32x │
│ 2021 │ 3,089 │ 1,353 │ 43.8% │ 624 │ 20.2% │ 2.17x │
│ 2022 │ 3,142 │ 1,320 │ 42.0% │ 715 │ 22.8% │ 1.85x │
│ 2023 │ 3,095 │ 1,265 │ 40.9% │ 782 │ 25.3% │ 1.62x │
│ 2024 │ 3,118 │ 1,228 │ 39.4% │ 846 │ 27.1% │ 1.45x │
│ 2025 │ 3,036 │ 1,176 │ 38.7% │ 900 │ 29.6% │ 1.31x │
│ 2026*│ 2,304 │ 900 │ 39.1% │ 565 │ 24.5% │ 1.59x │
└──────┴──────────────┴──────────────┴──────────────┴──────────────┴─────────────┴─────────────┘
*Note: 2026 data is year-to-date through the August 1, 2026 AACT snapshot; not annualized.
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ BREAKDOWN OF 2021 VS. 2025 STRICT PHASE 1 TRIAL SITES │
├──────────────────────────────────────┬───────────────────────┬───────────────────────────────┤
│ Geographic Distribution Subset │ 2021 Count (Share) │ 2025 Count (Share) │
├──────────────────────────────────────┼───────────────────────┼───────────────────────────────┤
│ Total Strict Phase 1 Trials │ 3,089 (100.0%) │ 3,036 (100.0%) │
│ United States Site(s) Present │ 1,353 (43.8%) │ 1,176 (38.7%) │
│ China Site(s) Present │ 624 (20.2%) │ 900 (29.6%) │
│ United States Only (No China site) │ 1,334 (43.2%) │ 1,144 (37.7%) │
│ China Only (No US site) │ 605 (19.6%) │ 868 (28.6%) │
│ Multinational (Both US & China sites)│ 19 (0.6%) │ 32 (1.1%) │
│ No country listed │ 117 (3.8%) │ 239 (7.9%) │
└──────────────────────────────────────┴───────────────────────┴───────────────────────────────┘
The 117 (2021) and 239 (2025) rows are studies with no country listed in AACT. They are not a rest-of-world bucket. After subtracting U.S.-only, China-only, both-country, and no-country rows, the remainder had sites in other countries (1,014 in 2021; 753 in 2025).
Empirical Findings vs. Agency Statements
Our independent recomputation reveals two critical findings:
- China Never Surpassed the US in ClinicalTrials.gov Site Count: On a direct trial-site basis, the United States maintained more Phase 1 clinical trial starts than China in every single calendar year from 2016 through 2025. In 2021, the U.S. hosted 1,353 Phase 1 studies compared to China's 624 (a 2.17-to-1 ratio). By 2025, while the U.S. count contracted to 1,176, China reached 900 (a 1.31-to-1 ratio). Including combined Phase 1/Phase 2 protocols (
PHASE1/PHASE2) yields the exact same qualitative result. - The Shift in Domestic Share is Real: Although China did not overtake the U.S. in absolute ClinicalTrials.gov registrations, China's domestic-only Phase 1 trials expanded by 396% between 2016 (175 trials) and 2025 (868 trials). Over the same decade, the U.S. share of global Phase 1 studies registered on ClinicalTrials.gov declined from 53.8% to 38.7%.
Thus, FDA's statement that China "surpassed the US in global share in 2021" must be understood as referring to a specific proprietary registry metric (or a total protocol census including domestic Chinese registry data from the NMPA/CDE that is not cross-registered on ClinicalTrials.gov), rather than a crossover in ClinicalTrials.gov site presence.
The rapid rise of Chinese domestic FIH capacity—particularly in advanced cell and gene therapies, as detailed in our analysis of in vivo CAR-T clinical trial dynamics and global cell and gene therapy trial volumes—forms the true competitive driver behind FDA's initiative. However, sponsors utilizing Chinese trial data must remain mindful of the regulatory constraints and inspection standards governing foreign clinical studies, as examined in our review of the FDA China clinical-trial data Moolenaar letter.
What Happens After August 24: Unpacking Speculative Timelines
With comments closing on August 24, several trade publications and legal advisory notes have published speculative timelines asserting that FDA will launch formal QRI applications in September 2026 and initiate rolling pilot reviews in the fourth quarter of 2026.
Biopharma sponsors must treat these scheduling rumors with caution:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ FACT VS. SPECULATION: EXPEDITED IND TIMELINE AUDIT │
├────────────────────────────┬─────────────────────────────┬───────────────────────────────────┤
│ Timeline Element │ Official FR Docket Status │ Trade / Advisory Speculation │
├────────────────────────────┼─────────────────────────────┼───────────────────────────────────┤
│ Public Comment Close │ Confirmed: August 24, 2026 │ Closed as scheduled. │
│ Final Pilot Guidance / SOP │ NOT in FR Notice (Pending) │ Speculated for Late 2026 / Q1 2027│
│ QRI Application Window │ NOT in FR Notice │ Speculated for September 2026 │
│ Operational Pilot Launch │ NOT in FR Notice │ Speculated for Q4 2026 │
│ Statutory 30-Day Change │ Explicitly NOT Proposed │ Misunderstood as 14-day review │
└────────────────────────────┴─────────────────────────────┴───────────────────────────────────┘
The June 24 RFI (FR Doc. 2026-12621) and July 21 extension (FR Doc. 2026-14672) contain no binding launch dates, no formal QRI selection criteria, and no administrative application window. Under Good Guidance Practices (21 CFR 10.115), the agency must evaluate docket comments, formulate an operational pilot charter, and publish formal procedural guidance or a Standard Operating Procedure (SOP) before formally enrolling sponsors and QRIs.
Operational Takeaways for Early-Stage Biopharma Sponsors
As FDA transitions from public consultation to pilot design, early-stage biotechnology sponsors, academic investigators, and translational teams should implement a disciplined four-step strategy:
┌──────────────────────────────────────────────────────────────────────────────────────────────┐
│ SPONSOR ACTION PLAN: NAVIGATING FIH IND WORKFLOWS │
├──────────────────────────┬───────────────────────────────────────────────────────────────────┤
│ Strategic Step │ Operational Implementation Focus │
├──────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 1. Maintain Traditional │ • Do not pause planned 2026–2027 IND filings in anticipation of │
│ Pre-IND Readiness │ the pilot. Continue standard INTERACT and Pre-IND meetings. │
│ │ • Build complete Module 3 (CMC) and Module 4 (Tox) packages. │
├──────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 2. Audit Potential QRI │ • If partnering with an AMC or CRO for early review, verify that │
│ Partnerships │ their toxicology and CMC review standards strictly align with │
│ │ CDER/CBER review division expectations. │
├──────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 3. Parallelize IRB and │ • Use central IRBs and parallel institutional review during the │
│ Site Qualification │ pre-IND window so clinical sites are cleared to activate the │
│ │ moment the § 312.40 30-day clock elapses. │
├──────────────────────────┼───────────────────────────────────────────────────────────────────┤
│ 4. Track Official FDA │ • Monitor the agency's clinical development modernization hub │
│ Charter Guidance │ for formal QRI qualification criteria and pilot cohort limits. │
└──────────────────────────┴───────────────────────────────────────────────────────────────────┘
1. Do Not Delay Current Development Programs
Sponsors with FIH milestones in late 2026 or early 2027 should not delay submissions in hopes of participating in the pilot. Standard Pre-IND meetings (Type B meetings under PDUFA VII) remain the gold standard for securing formal, binding regulatory feedback from CDER and CBER review divisions.
2. Treat Third-Party Reviews as Risk-Reduction, Not Risk-Elimination
Third-party advisory opinions from academic institutions or CROs are highly valuable for refining pharmacokinetic/pharmacodynamic (PK/PD) modeling and starting-dose rationales. However, sponsors must remember that liability and regulatory responsibility under 21 CFR Part 312 rest solely with the sponsor-investigator.
3. Focus on CMC and Assay Validation
In early-phase development—especially for complex biologics, mRNA therapies, and individualized cell products—the overwhelming driver of Phase 1 clinical holds is CMC and potency characterization rather than clinical protocol mechanics. Front-loading analytical characterization and stability testing remains the most reliable strategy to ensure an IND proceeds without hold on Day 30.
Frequently Asked Questions
Does the Expedited IND Pilot Program replace the 30-day IND safe-to-proceed clock?
No. Under 21 CFR § 312.40(b)(1), an IND goes into effect 30 days after FDA receives it unless FDA imposes a clinical hold. Under § 312.40(b)(2), it can go into effect earlier if FDA notifies the sponsor that the investigations may begin. The pilot does not amend § 312.40. Rolling CMC and nonclinical modules plus QRI pre-review may make a (b)(2) notice more realistic; they do not replace the 30-day default.
When do public comments close on the Expedited IND Pilot, and what is the docket number?
The comment period closed on August 24, 2026 (extended from the original July 22, 2026 deadline by FR Doc. 2026-14672). Submissions are recorded under Docket No. FDA-2026-N-4699 on Regulations.gov.
Can a Qualified Research Institution impose or lift an FDA clinical hold?
No. Under 21 CFR § 312.42, only the FDA has the legal authority to place an investigational study on clinical hold or to authorize the resumption of a trial following a hold. QRI review is strictly advisory and third-party.
Did China surpass the United States in Phase 1 clinical trials in 2021 on ClinicalTrials.gov?
No. An independent recomputation of the AACT/ClinicalTrials.gov database (snapshot August 1, 2026) demonstrates that the United States maintained more Phase 1 interventional study starts than China in every year from 2016 through 2025. In 2021, the U.S. recorded 1,353 strict Phase 1 trials versus 624 in China. However, China's domestic-only Phase 1 trials grew from 175 in 2016 to 868 in 2025, significantly expanding China's global trial share.
What types of institutions qualify as a QRI under the proposed pilot?
The June 24 RFI proposed that QRIs could include academic medical centers, major hospital and healthcare networks, established contract research organizations (CROs), and specialized regulatory consulting organizations that demonstrate rigorous nonclinical, clinical, and CMC review capabilities.
Sources
- U.S. Food and Drug Administration. "Expedited Investigational New Drug Pilot Program; Request for Information." Federal Register, Vol. 91, No. 121, June 24, 2026, pp. 37996–38000 (FR Doc. 2026-12621; Docket No. FDA-2026-N-4699). Available at: FederalRegister.gov.
- U.S. Food and Drug Administration. "Expedited Investigational New Drug Pilot Program; Request for Information; Extension of the Comment Period." Federal Register, Vol. 91, No. 139, July 21, 2026, p. 45820 (FR Doc. 2026-14672; Docket No. FDA-2026-N-4699). Available at: FederalRegister.gov.
- Electronic Code of Federal Regulations. "21 CFR § 312.40 — General requirements for use of an investigational new drug in a clinical investigation." Title 21, Chapter I, Subchapter D, Part 312, Subpart C. Available at: eCFR.gov.
- Electronic Code of Federal Regulations. "21 CFR § 312.42 — Clinical holds and requests for modification." Title 21, Chapter I, Subchapter D, Part 312, Subpart C. Available at: eCFR.gov.
- Clinical Trials Transformation Initiative (CTTI). Aggregate Analysis of ClinicalTrials.gov (AACT) Database. Pipe-delimited dataset snapshot dated August 1, 2026. Studies and Countries tables analyzed for Interventional Phase 1 and Early Phase 1 clinical studies.
- U.S. Food and Drug Administration. "FDA Actions to Accelerate and Modernize Early and Late-Stage Clinical Development." Agency Program Hub, Content current as of August 2026. Available at: FDA.gov Industry Guidance.
- U.S. Food and Drug Administration. "Expedited IND Pilot Program Educational Webinar for Stakeholders." Public Webinar Archive, August 6, 2026. Available at: FDA.gov Meetings & Workshops.
